Tweets
SLE Pipeline of New Therapies
Dr. Andrea Fava, EULAR 2026 in London.
https://t.co/GwntaPwzWr https://t.co/prFnaSKuqF
Dr. John Cush @RheumNow ( View Tweet )
1 hour 59 minutes ago
Treat to Target Works in Elderly Onset RA
Dr. Jiha Lee reports on abstract POS1326 at EULAR 2026 in London
https://t.co/X4vhR9KofC https://t.co/TSquFmZJCP
Dr. John Cush @RheumNow ( View Tweet )
2 hours 59 minutes ago
Digital Platforms and AI
Work was presented from three PARE initiatives that showcase how digital tools can be used in treatment education and decision-making, and potentially avoid the use of general web searches to answer important questions.
https://t.co/LxXeFdAbU7 https://t.co/ocqSBhYHEf
Dr. John Cush @RheumNow ( View Tweet )
4 hours 59 minutes ago
Digital Patient Education in RA
Dr. Bella Mehta reviews abstract OP005-HPR presented in London at EULAR 2026
https://t.co/Wj8omKJTNx. https://t.co/h13p54BAHs
Dr. John Cush @RheumNow ( View Tweet )
5 hours 59 minutes ago
Understanding Comorbidities in RMD
People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. EIULAR 2026 showcased new data and ideas around various comorbidities and https://t.co/twr0EiMp9f
Dr. John Cush @RheumNow ( View Tweet )
6 hours 59 minutes ago
All content is independently chosen and produced by the RheumNow faculty. RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB.
Dr. John Cush @RheumNow ( View Tweet )
8 hours 58 minutes ago
Day 1 Report from EULAR 2026
The first day of EULAR 2026 in London featured the opening ceremonies, a plenary session, posters nd the first round of major oral presentations to an audience of nearly 15,000 attendees. Here are a few of my favorites from the first day. https://t.co/qCnoiGedat
Dr. John Cush @RheumNow ( View Tweet )
9 hours 59 minutes ago
The pain that inflammation does not explain in SpA and PsA
At EULAR 2026, the NEUPIA study (OP0317), a prospective observational investigation conducted at KU Leuven and University Hospitals Leuven, provides the most detailed longitudinal characterisation to date of these https://t.co/OYMf4KKBc1
Dr. John Cush @RheumNow ( View Tweet )
10 hours 59 minutes ago
#TYK2i #deucravacitinib
#RCT in #SLE
LTE of #PAISLEY #RCT PERSISTENT #LLDAS &#DORIS #remission over 3 more yrs post 1 yr RCT BUT ++dropouts
#POS0695 #EULAR2026 @RheumNow https://t.co/vtrMYrFmJ9
Janet Pope @Janetbirdope ( View Tweet )
11 hours 30 minutes ago
Who does better in active #RA
b/tsDMARD naive?
Pt choice TNFi or JAKi
OR
Pt randomized to
TNFI or JAKi?
Strangely or not
PT choice did better
✅with satisfaction ~maybe expected
✅better retention on chosen #Rx
🤔unexpected
another arm in #RCTS?”
#EULAR2026 @RheumNow
OP0204 https://t.co/7qx5Rqq6a7
Links:
Janet Pope @Janetbirdope ( View Tweet )
11 hours 30 minutes ago
Can you step down #belimumab
In well controlled #SLE without flaring?
N=22 on #BEL eligible of 152
Able to taper if
REM >6/12
No #steroids
Normal C3,C4
Neg #antiDNA
Remission maintained in pts who reduced dose
6/22 didn’t flare OFF Rx
✅nice
#POS1052 #EULAR2026
@RheumNow https://t.co/IEyfRtTGfT
Links:
Janet Pope @Janetbirdope ( View Tweet )
11 hours 30 minutes ago
A bridge to uncertainty?
large #RCT of #baricitinib V #TNFi
In
Active #RA w #DVT/#VTE risk factor(s)
Sl more VTE, #infection #SIE on #Bar
NO increase #MACE
Sl ⬆️#malignancy
#VTE rate exceeded upper limit of a priori #CI
So is this good news or not?
#LB0009 @RheumNow #EULAR2026 https://t.co/CIfU7TL2TE
Janet Pope @Janetbirdope ( View Tweet )
11 hours 30 minutes ago


